Biogen Stock News

Biogen (BIIB) is trading lower in the pre-market on Friday after disclosing that the U.S

Biogen''s new Alzheimer''s drug aduhelm saw limited pickup in its first few months on the market.

Shares of Biogen Inc. BIIB, -2.13% tumbled 2.2% in premarket trading on Friday after the company disclosed in a securities filing that it received a civil investigative demand from the Federal Trade C

The U.S. antitrust regulator has asked Biogen Inc to present documents related to the approval and marketing of its Alzheimer's disease treatment, the drugmaker disclosed in a filing.

BIIB earnings call for the period ending December 31, 2021.

BIIB earnings call for the period ending December 31, 2021.

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

Biogen, Inc. (NASDAQ: BIIB) Q4 2021 earnings call dated Feb. 03, 2022 Corporate Participants: Michael Hencke — Head of Investor Relations Michel Vounatsos — Chief Executive Officer Priya Singhal — Head of Global Safety & Regulatory […] The post Biogen, Inc. (BIIB) Q4 2021 Earnings Call Transcript first appeared on AlphaStreet .

Yves Lamoureux, president of Lamoureux & Co. is back with a new call. Investors should start buying certain hard-hit stocks again, but be prepared for plenty of ups and downs.

Biogen Inc (NASDAQ: BIIB ) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates. Biogen reported quarterly revenue of $2.73 billion, which beat the estimate of $2.62 billion. The company reported adjusted earnings of $3.39 per share, which came in below the $3.40 estimate. "Biogen continued to execute well in the fourth quarter despite the … Full story available on Benzinga.com

Biogen (BIIB) beats fourth-quarter estimates for both earnings and sales. The stock declines on weak sales and earnings guidance for 2022.

Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Syros' Blood Cancer Drugs Land Orphan Designation From FDA Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)